QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
NASDAQ:SELB

Selecta Biosciences - SELB Stock Forecast, Price & News

$2.39
-0.05 (-2.05%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.32
$2.50
50-Day Range
$1.05
$2.60
52-Week Range
$0.65
$4.70
Volume
1.72 million shs
Average Volume
1.63 million shs
Market Capitalization
$364.98 million
P/E Ratio
239.00
Dividend Yield
N/A
Price Target
$5.33

Selecta Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.2% Upside
$5.33 Price Target
Short Interest
Healthy
5.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
0.54mentions of Selecta Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$149,500 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From $0.18 to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

82nd out of 1,122 stocks

Pharmaceutical Preparations Industry

25th out of 551 stocks

SELB stock logo

About Selecta Biosciences (NASDAQ:SELB) Stock

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Analyst Ratings Changes

SELB has been the topic of several research reports. TheStreet raised Selecta Biosciences from a "d" rating to a "c-" rating in a research report on Wednesday, May 25th. StockNews.com raised Selecta Biosciences from a "hold" rating to a "buy" rating in a research report on Monday. Needham & Company LLC decreased their price target on Selecta Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, June 14th. SVB Leerink began coverage on shares of Selecta Biosciences in a research note on Monday, June 6th. They set an "outperform" rating and a $7.00 price objective on the stock. Finally, HC Wainwright decreased their target price on shares of Selecta Biosciences from $6.00 to $4.00 and set a "buy" rating for the company in a research note on Tuesday, June 21st. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Selecta Biosciences presently has a consensus rating of "Buy" and an average price target of $5.33.

Selecta Biosciences Stock Performance

NASDAQ:SELB traded down $0.02 during trading hours on Wednesday, reaching $2.42. 61,700 shares of the stock were exchanged, compared to its average volume of 2,070,679. The stock has a market capitalization of $369.56 million, a P/E ratio of 244.00 and a beta of 1.04. The firm has a 50 day simple moving average of $1.62 and a 200-day simple moving average of $1.44. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.25. Selecta Biosciences has a 52 week low of $0.65 and a 52 week high of $4.70.

Selecta Biosciences (NASDAQ:SELB - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. Selecta Biosciences had a net margin of 24.85% and a return on equity of 11.30%. During the same period in the prior year, the firm earned ($0.04) earnings per share. As a group, sell-side analysts forecast that Selecta Biosciences will post 0.18 earnings per share for the current fiscal year.

Insider Activity at Selecta Biosciences

In other Selecta Biosciences news, Director Carrie Smith Cox bought 130,000 shares of the business's stock in a transaction on Monday, June 13th. The shares were purchased at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now directly owns 212,881 shares of the company's stock, valued at approximately $244,813.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 30.50% of the company's stock.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

Expert Ratings for Selecta Biosciences
7 Cheap Biotech Stocks to Buy Now
See More Headlines
Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Company Calendar

Last Earnings
8/04/2022
Today
8/17/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SELB
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+123.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-25,690,000.00
Pretax Margin
37.36%

Debt

Sales & Book Value

Annual Sales
$85.08 million
Book Value
$0.59 per share

Miscellaneous

Free Float
106,136,000
Market Cap
$364.98 million
Optionable
Optionable
Beta
1.04

Key Executives














SELB Stock - Frequently Asked Questions

Should I buy or sell Selecta Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SELB shares.
View SELB analyst ratings
or view top-rated stocks.

What is Selecta Biosciences' stock price forecast for 2022?

3 analysts have issued 1-year price targets for Selecta Biosciences' shares. Their SELB share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 124.1% from the stock's current price.
View analysts price targets for SELB
or view top-rated stocks among Wall Street analysts.

How have SELB shares performed in 2022?

Selecta Biosciences' stock was trading at $3.26 at the beginning of 2022. Since then, SELB stock has decreased by 27.0% and is now trading at $2.38.
View the best growth stocks for 2022 here
.

When is Selecta Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SELB earnings forecast
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its quarterly earnings data on Thursday, August, 4th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. Selecta Biosciences had a trailing twelve-month return on equity of 11.30% and a net margin of 24.85%. During the same period in the previous year, the company posted ($0.04) earnings per share.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Artal Group S.A. (3.22%), NanoDimension Inc. (2.64%), JPMorgan Chase & Co. (1.10%), Millennium Management LLC (0.85%), AQR Capital Management LLC (0.84%) and FMR LLC (0.77%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends
.

How do I buy shares of Selecta Biosciences?

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $2.38.

How much money does Selecta Biosciences make?

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $363.45 million and generates $85.08 million in revenue each year. The company earns $-25,690,000.00 in net income (profit) each year or $0.01 on an earnings per share basis.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.

This page (NASDAQ:SELB) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.